Chronic hepatitis C virus (HCV) infection is one of the most common causes of liver cirrhosis and hepatocellular carcinoma in China. The older standard treatment regimen for chronic hepatitis C was the pegylated interferon-alfa plus ribavirin(PR). Now newer oral medications called direct antiviral agents (DAAs) has been gradually changed to PR-based DAAs and interferon-free, oral DAAs; making chronic hepatitis C a curable disease. This article intends to expound the advantages and disadvantages of PR-based therapy and provide reference for the treatment of chronic hepatitis C.
慢性丙型肝炎病毒感染是我国肝硬化以及肝细胞癌的病因之一。在直接抗病毒药物（DAAs）上市之前，我国慢性丙型肝炎的标准治疗方案为聚乙二醇干扰素α联合利巴韦林的PR方案。随着DAAs的不断上市，我国慢性丙型肝炎治疗已逐渐过渡为以PR为基础联合DAAs及无干扰素的全口服DAAs方案，使慢性丙型肝炎成为可治愈的疾病。现拟对以PR为基础治疗慢性丙型肝炎的优势和不足进行阐述，为我国丙型肝炎的治疗提供参考。.
Keywords: Direct-acting antiviral agents; Hepatitis C, chronic; Interferon-alpha; Ribavirin.